Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Rakuten Medical’s Photoimmunotherapy Now Available in Japan
Rakuten Medical Japan said on February 8 that it has launched its photoimmunotherapy agent Akalux (cetuximab sarotalocan sodium) along with a laser system called BioBlade for the treatment of unresectable locally advanced or recurrent head and neck cancer. Akalux is…
To read the full story
Related Article
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Rakuten Medical Eyes Label Expansion for Photoimmunotherapy, Asia as Key Market
August 26, 2021
- Medipal to Take on Akalux Distribution in Japan, Rakuten’s Photoimmunotherapy
January 13, 2021
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Rakuten Medical’s Photoimmunotherapy Filed in Japan, Subject to Conditional Early OK
July 1, 2020
- Mikitani Resolved to Grow Rakuten Medical into Global Biotech
July 2, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…